<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The purpose of this study was to investigate the mechanisms by which a nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> synthase (NOS) inhibitor, NG-<z:chebi fb="13" ids="29785">nitro</z:chebi>-<z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> <z:chebi fb="36" ids="29309">methyl</z:chebi> <z:chebi fb="21" ids="35701">ester</z:chebi> (L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e>), is neuroprotective in the hyperglycemic rat model of 2 h of transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> followed by 2 h of reperfusion (MCAO/R) </plain></SENT>
<SENT sid="1" pm="."><plain>The <z:chebi fb="1" ids="30762">salicylate</z:chebi> trapping method was used in conjunction with a microdialysis technique to continuously estimate <z:chebi fb="1" ids="29191">hydroxyl radical</z:chebi> (.OH) formation by measurement of the stable adducts 2,3- and <z:chebi fb="0" ids="17189">2,5-dihydroxybenzoic acid</z:chebi> (DHBA) </plain></SENT>
<SENT sid="2" pm="."><plain>Extracellular excitatory amino acids (EAAs) were detected from the same microdialysis samples </plain></SENT>
<SENT sid="3" pm="."><plain>Magnetic resonance imaging (MRI) techniques were used to measure neuronal and cerebrovascular injury </plain></SENT>
<SENT sid="4" pm="."><plain>The magnitude of EAA release correlated with the levels of the .OH adducts </plain></SENT>
<SENT sid="5" pm="."><plain>Treatment with L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> (3 mg/kg, i.p.) 1 min before MCAO, and again 1 min before reperfusion, reduced the levels of DHBA by 46 </plain></SENT>
<SENT sid="6" pm="."><plain>4% and <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> by 50.5% in the hyperglycemic rats compared to untreated hyperglycemic controls </plain></SENT>
<SENT sid="7" pm="."><plain>MRI indicated that L-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> reduced the no-reflow zone and the cytotoxic lesion volume to 22.5% and 21 </plain></SENT>
<SENT sid="8" pm="."><plain>0%, respectively, that of hyperglycemic controls </plain></SENT>
<SENT sid="9" pm="."><plain>Co-treatment with the nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> (NO) donor <z:chebi fb="0" ids="16467,29952">L-arginine</z:chebi> completely eliminated the protective effects of l-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">NAME</z:e> with respect to .OH and EAA levels as well as MRI lesion volume </plain></SENT>
<SENT sid="10" pm="."><plain>Our data suggest that hyperglycemic MCAO/R results in excessive <z:chebi fb="6" ids="14321,29987">glutamate</z:chebi> excitotoxicity, leading to enhanced generation of .OH via a NO-mediated mechanism, in turn resulting in severe <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e>/reperfusion brain injury </plain></SENT>
</text></document>